Up-regulating Blood Brain Barrier Permeability of Nanoparticles Via Multivalent Effect

Xihui Gao,Jun Qian,Shuyan Zheng,Ying Xiong,Jiahao Man,Binxin Cao,Lu Wang,Shenghong Ju,Cong Li

DOI: https://doi.org/10.1007/s11095-013-1004-9

IF: 4.58

2013-01-01

Pharmaceutical Research

Abstract:To investigate the multivalent effect for up-regulating the intracerebral delivery of nanoparticles via receptor-mediated transcytosis.

What problem does this paper attempt to address?

Transferrin-conjugated, fluorescein-loaded magnetic nanoparticles for targeted delivery across the blood–brain barrier

Feng Yan,Ying Wang,Shenzhi He,Shuting Ku,Wei Gu,Ling Ye

DOI: https://doi.org/10.1007/s10856-013-4993-3

2013-01-01

Abstract:The blood–brain barrier (BBB) restricts the delivery of many potentially important therapeutic agents for the treatment of brain disorders. An efficient strategy for brain targeted delivery is the utilization of the targeting ligand conjugated nanoparticles to trigger the receptor-mediated transcytosis. In this study, transferrin (Tf) was employed as a brain targeting ligand to functionalize the fluorescein-loaded magnetic nanoparticles (FMNs). The Tf conjugated FMNs (Tf-FMNs) were characterized by transmission electron microscopy, thermal gravimetric analysis, Fourier transform infrared spectroscopy, and X-ray photoelectron spectroscopy. Using fluorescein as an optical probe, the potential of Tf-FMNs as brain targeting drug carriers was explored in vivo. It was demonstrated that Tf-FMNs were able to cross the intact BBB, diffuse into brain neurons, and distribute in the cytoplasm, dendrites, axons, and synapses of neurons. In contrast, magnetic nanoparticles without Tf conjugation cannot cross the BBB efficiently under the same conditions. Therefore, Tf-FMNs hold great potential in serving as an efficient multifunctional platform for the brain-targeted theranostics.
Advancements in strategies for overcoming the blood-brain barrier to deliver brain-targeted drugs

Zhichuang Qu,Juan Luo,Zheng Li,Rong Yang,Jiaxi Zhao,Xin Chen,Sixun Yu,Haifeng Shu

DOI: https://doi.org/10.3389/fnagi.2024.1353003

2024-08-26

Abstract:The blood-brain barrier is known to consist of a variety of cells and complex inter-cellular junctions that protect the vulnerable brain from neurotoxic compounds; however, it also complicates the pharmacological treatment of central nervous system disorders as most drugs are unable to penetrate the blood-brain barrier on the basis of their own structural properties. This dramatically diminished the therapeutic effect of the drug and compromised its biosafety. In response, a number of drugs are often delivered to brain lesions in invasive ways that bypass the obstruction of the blood-brain barrier, such as subdural administration, intrathecal administration, and convection-enhanced delivery. Nevertheless, these intrusive strategies introduce the risk of brain injury, limiting their clinical application. In recent years, the intensive development of nanomaterials science and the interdisciplinary convergence of medical engineering have brought light to the penetration of the blood-brain barrier for brain-targeted drugs. In this paper, we extensively discuss the limitations of the blood-brain barrier on drug delivery and non-invasive brain-targeted strategies such as nanomedicine and blood-brain barrier disruption. In the meantime, we analyze their strengths and limitations and provide outlooks on the further development of brain-targeted drug delivery systems.
Regulation of cerebral blood flow boosts precise brain targeting of vinpocetine-derived ionizable-lipidoid nanoparticles

Xufei Bian,Ling Yang,Dingxi Jiang,Adam J Grippin,Yifan Ma,Shuang Wu,Linchong Wu,Xiaoyou Wang,Zhongjie Tang,Kaicheng Tang,Weidong Pan,Shiyan Dong,Betty Y S Kim,Wen Jiang,Zhaogang Yang,Chong Li

DOI: https://doi.org/10.1038/s41467-024-48461-4

2024-05-11

Abstract:Despite advances in active drug targeting for blood-brain barrier penetration, two key challenges persist: first, attachment of a targeting ligand to the drug or drug carrier does not enhance its brain biodistribution; and second, many brain diseases are intricately linked to microcirculation disorders that significantly impede drug accumulation within brain lesions even after they cross the barrier. Inspired by the neuroprotective properties of vinpocetine, which regulates cerebral blood flow, we propose a molecular library design centered on this class of cyclic tertiary amine compounds and develop a self-enhanced brain-targeted nucleic acid delivery system. Our findings reveal that: (i) vinpocetine-derived ionizable-lipidoid nanoparticles efficiently breach the blood-brain barrier; (ii) they have high gene-loading capacity, facilitating endosomal escape and intracellular transport; (iii) their administration is safe with minimal immunogenicity even with prolonged use; and (iv) they have potent pharmacologic brain-protective activity and may synergize with treatments for brain disorders as demonstrated in male APP/PS1 mice.
Influence factors on and potential strategies to amplify receptor-mediated nanodrug delivery across the blood–brain barrier

Ya Wei,Xue Xia,Hanmei Li,Huile Gao

DOI: https://doi.org/10.1080/17425247.2023.2245332

2023-08-12

Expert Opinion on Drug Delivery

Abstract:A major challenge in treating central nervous system (CNS) disorders is to achieve adequate drug delivery across the blood–brain barrier (BBB). Receptor-mediated nanodrug delivery as a Trojan horse strategy has become an exciting approach. However, these nanodrugs do not accumulate significantly in the brain parenchyma, which greatly limits the therapeutic effect of drugs. Amplifying the efficiency of receptor-mediated nanodrug delivery across the BBB becomes the holy grail in the treatment of CNS disorders. In this review, we tend to establish links between dynamic BBB and receptor-mediated nanodrug delivery, starting with the delivery processes across the BBB, describing factors affecting nanodrug delivery efficiency, and summarizing potential strategies that may amplify delivery efficiency. Receptor-mediated nanodrug delivery is a common approach to significantly enhance the efficiency of brain-targeting delivery. As BBB is constantly undergoing changes, it is essential to investigate the impact of diseases on the effectiveness of brain-targeting nanodrug delivery. More critically, there are several barriers to achieving brain-targeting nanodrug delivery in the five stages of receptor-mediated transcytosis (RMT), and the impacts can be conflicting, requiring intricate balance. Further studies are also needed to investigate the material toxicity of nanodrugs to address the issue of clinical translation.

pharmacology & pharmacy
Research Progress in Brain-Targeting Drug Delivery Systems

JIANG Xin-guo

DOI: https://doi.org/10.3969/j.issn.1672-8467.2012.05.001

2012-01-01

Abstract:Receptors and transporters such as transferrin receptor,low density lipoprotein receptor and glucose transporter are found expressed on the blood-brain barrier.Functionalization of drug delivery systems with ligands or antibodies of these receptors or transporter can enable brain to enhance drug delivery,improve treatment efficiency and reduce adverse effects.Besides,brain drug delivery can also be facilitated via absorption-mediated transcytosis or following intranasal administration.
Strategies for transporting nanoparticles across the blood-brain barrier.

Tian-Tian Zhang,Wen Li,Guanmin Meng,Pei Wang,Wenzhen Liao

DOI: https://doi.org/10.1039/c5bm00383k

2016-01-01

Biomaterials Science

Abstract:The existence of blood-brain barrier (BBB) hampers the effective treatment of central nervous system (CNS) diseases. Almost all macromolecular drugs and more than 98% of small molecule drugs cannot pass the BBB. Therefore, the BBB remains a big challenge for delivery of therapeutics to the central nervous system. With the structural and mechanistic elucidation of the BBB under both physiological and pathological conditions, it is now possible to design delivery systems that could cross the BBB effectively. Because of their advantageous properties, nanoparticles have been widely deployed for brain-targeted delivery. This review paper presents the current understanding of the BBB under physiological and pathological conditions, and summarizes strategies and systems for BBB crossing with a focus on nanoparticle-based drug delivery systems. In summary, with wider applications and broader prospection the treatment of brain targeted therapy, nano-medicines have proved to be more potent, more specific and less toxic than traditional drug therapy.
Magnetic resonance imaging with upconversion nanoprobes capable of crossing the blood-cerebrospinal fluid barrier

Fang Han,Jiahao Gao,Guanglei Lv,Tao Liu,Qingfeng Hu,Meilin Zhu,Zunguo Du,Jing Yang,Zhenwei Yao,Xiangming Fang,Dalong Ni,Jiawen Zhang

DOI: https://doi.org/10.1186/s12951-024-02301-1

IF: 10.2

2024-02-01

Journal of Nanobiotechnology

Abstract:The central nervous system (CNS) maintains homeostasis with its surrounding environment by restricting the ingress of large hydrophilic molecules, immune cells, pathogens, and other external harmful substances to the brain. This function relies heavily on the blood-cerebrospinal fluid (B-CSF) and blood-brain barrier (BBB). Although considerable research has examined the structure and function of the BBB, the B-CSF barrier has received little attention. Therapies for disorders associated with the central nervous system have the potential to benefit from targeting the B-CSF barrier to enhance medication penetration into the brain. In this study, we synthesized a nanoprobe ANG-PEG-UCNP capable of crossing the B-CSF barrier with high targeting specificity using a hydrocephalus model for noninvasive magnetic resonance ventriculography to understand the mechanism by which the CSF barrier may be crossed and identify therapeutic targets of CNS diseases. This magnetic resonance nanoprobe ANG-PEG-UCNP holds promising potential as a safe and effective means for accurately defining the ventricular anatomy and correctly locating sites of CSF obstruction.

biotechnology & applied microbiology,nanoscience & nanotechnology
Advanced Noninvasive Strategies for the Brain Delivery of Therapeutic Proteins and Peptides

Jiayuan Lin,Zhihua Yu,Xiaoling Gao

DOI: https://doi.org/10.1021/acsnano.4c06851

IF: 17.1

2024-08-27

ACS Nano

Abstract:Recent years have witnessed rapid progress in the discovery of therapeutic proteins and peptides for the treatment of central nervous system (CNS) diseases. However, their clinical applications have been considerably hindered by challenges such as low biomembrane permeability, poor stability, short circulation time, and the formidable blood-brain barrier (BBB). Recently, substantial improvements have been made in understanding the dynamics of the BBB and developing efficient approaches for delivering proteins and peptides to the CNS, especially by using various nanoparticles. Herein, we present an overview of the up-to-date understanding of the BBB under physiological and pathological conditions, emphasizing their effects on brain drug delivery. We summarize advanced strategies and elucidate the underlying mechanisms for delivering proteins and peptides to the brain. We highlight the developments and applications of nanocarriers in treating CNS diseases via BBB crossing. We also provide critical opinions on the limitations and obstacles of the current strategies and put forward prospects for future research.
Brain-targeted nanoparticle drug delivery systems:research advances

CAO Yi,JIANG Chen

DOI: https://doi.org/10.16352/j.issn.1001-6325.2022.01.007

2022-01-01

Abstract:The blood-brain barrier (BBB) is a special structure in the central nervous system (CNS), whose delicate properties can protect the brain from the attack by harmful large molecules and organisms within blood circulation. However, the very barrier also prevents the brain-targeted drugs from taking effects, posing great challenge to the treatment of neurodegenerative diseases, glioma and other brain diseases. With the development of nanotechnology, more and more nanoparticles (NPs) have been developed as drug carriers, which can facilitate the drug with various mechanisms to get across the BBB. This article starts with introduction of the BBB, explaining the complexity of BBB structure and its unique features to form barriers, so that we can understand the difficulty in transporting drug into the BBB and the potential methods of targeting and permeate the barrier. Next, we focus on three main types of NPs that have been applied in the brain-targeted drug delivery system: polymeric-based NPs; biomimetic-based NPs and inorganic-based NPs. Furthermore, we deal with the specific NPs drug delivery strategies, which include absorption-mediated, carrier-mediated and receptor-mediated transcytosis. At the end of the article, we talk about the leading trend and future development of the brain-targeted nanoparticle drug delivery systems.
Advancing Central Nervous System Drug Delivery with Microtubule-Dependent Transcytosis of Novel Aqueous Compounds

Mingzhu Zhang,Shaoqi Zhong,Lujing An,Pan Xiang,Na Hu,Wei Huang,Yupeng Tian,Giuseppe Battaglia,Xiaohe Tian,Min Wu

DOI: https://doi.org/10.34133/bmr.0051

2024-07-24

Abstract:The challenge of delivering therapeutics to the central nervous system due to the restrictive nature of the blood-brain barrier (BBB) is a substantial hurdle in neuropharmacology. Our research introduces a breakthrough approach using microtubule-dependent transcytosis facilitated by novel aqueous compounds. We synthesized a series of red-emitting pyran nitrile derivatives. The molecular structure of compounds, photophysical properties, and water solubility were characterized. BBB permeability of BN1 was assessed in an in vitro BBB model. The transmembrane transport mechanism was next analyzed. The derivative was injected in the wild-type mouse for evaluation of brain penetration and biodistribution in the brain. We further investigated the potential of BN1-functionalized BBB-nonpenetrated silica nanoparticles for brain targeting. This compound demonstrated an ability to form endosomes within the phospholipid layer, thus enabling efficient penetration of the BBB via microtubule-mediated transcytosis, as evidenced in vitro model. This was further confirmed by in vivo experiments that BN1 displays the excellent BBB penetration and retained in brain parenchyma. Furthermore, BBB-impermeable mesoporous silica nanoparticle codelivery system markedly enhanced the transport efficiency to the brain in vivo by BN1-functionalized. These findings indicate that our designed aqueous molecules not only are capable of traversing the BBB but also serve as a viable new strategy for central-nervous-system-targeted drug delivery.
Modulation of the Blood–Brain Barrier for Drug Delivery to Brain

Liang Han

DOI: https://doi.org/10.3390/pharmaceutics13122024

IF: 6.525

2021-01-01

Pharmaceutics

Abstract:The blood–brain barrier (BBB) precisely controls brain microenvironment and neural activity by regulating substance transport into and out of the brain. However, it severely hinders drug entry into the brain, and the efficiency of various systemic therapies against brain diseases. Modulation of the BBB via opening tight junctions, inhibiting active efflux and/or enhancing transcytosis, possesses the potential to increase BBB permeability and improve intracranial drug concentrations and systemic therapeutic efficiency. Various strategies of BBB modulation have been reported and investigated preclinically and/or clinically. This review describes conventional and emerging BBB modulation strategies and related mechanisms, and safety issues according to BBB structures and functions, to try to give more promising directions for designing more reasonable preclinical and clinical studies.
Overcoming the Blood-Brain Barrier for Delivering Drugs into the Brain by Using Adenosine Receptor Nanoagonist.

Xihui Gao,Jun Qian,Shuyan Zheng,Yinzhi Changyi,Jianping Zhang,Shenghong Ju,Jianhua Zhu,Cong Li

DOI: https://doi.org/10.1021/nn5003375

IF: 17.1

2014-01-01

ACS Nano

Abstract:The extremely low permeability of the blood-brain barrier (BBB) poses the greatest impediment in the treatment of central nervous system (CNS) diseases. Recent work indicated that BBB permeability can be up-regulated by activating A2A adenosine receptor (AR), which temporarily increases intercellular spaces between the brain capillary endothelial cells. However, due to transient circulation lifetime of adenosine-based agonists, their capability to enhance brain delivery of drugs, especially macromolecular drugs, is limited. In this work, a series of nanoagonists (NAs) were developed by labeling different copies of A2A AR activating ligands on dendrimers. In vitro transendothelial electrical resistance measurements demonstrated that the NAs increased permeability of the endothelial cell monolayer by compromising the tightness of tight junctions, the key structure that restricts the entry of blood-borne molecules into the brain. In vivo imaging studies indicated the remarkably up-regulated brain uptake of a macromolecular model drug (45 kDa) after intravenous injection of NAs. Autoradiographic imaging showed that the BBB opening time-window can be tuned in a range of 0.5-2.0 h by the NAs labeled with different numbers of AR-activating ligands. By choosing a suitable NA, it is possible to maximize brain drug delivery and minimize the uncontrollable BBB leakage by matching the BBB opening time-window with the pharmacokinetics of a therapeutic agent. The NA-mediated brain drug delivery strategy holds promise for the treatment of CNS diseases with improved therapeutic efficiency and reduced side-effects.
Clearance of Two Organic Nanoparticles from the Brain Via the Paravascular Pathway.

Xiao Gu,Qingxiang Song,Qian Zhang,Meng Huang,Mengna Zheng,Juan Chen,Dan Wei,Jun Chen,Xunbin Wei,Hongzhuan Chen,Gang Zheng,Xiaoling Gao

DOI: https://doi.org/10.1016/j.jconrel.2020.03.009

IF: 11.467

2020-01-01

Journal of Controlled Release

Abstract:The elaboration of nanotechnology offers valuable therapeutic options to overcome the blood-brain barrier and enable the treatment of brain diseases. However, to date, limit work has been done to reveal the fate of nanoparticles within the brain, which largely hinders their safe and effective applications. Here we demonstrated that the commonly-used organic nanoparticles reconstituted high density lipoprotein and poly(ethylene glycol)-b-poly(lactic acid) nanoparticles were cleared relatively fast from the brain (half-life <5 h). Notably, through various transgenic mice and pharmacological inhibition approaches, we revealed that the paravascular glymphatic pathway plays a key role (about 80%) in the brain clearance of the nanoparticles, and disclosed that microglia-mediated transportation is essential for facilitating nanoparticles elimination through the paravascular route. In addition, we witnessed a significant decline in the brain clearance of both of the nanoparticles in Alzheimer's model mice where the glymphatic system is impaired. These findings provide insightful data on the fate of nanoparticles in the brain, which would shed new light into the rational design and safe application of nanoparticles for brain drug delivery.
Study on Brain Targeted Drug Delivery Nanoparticles

张阳德,刘美洲,刘东京,丁诚,龚连生

DOI: https://doi.org/10.3969/j.issn.1005-8982.2008.10.021

2008-01-01

Abstract:The existence of blood-brain barrier (BBB) is an unfavorable factor in the treat-ment of central nervous system (CNS) diseases. The following advances were reviewed in this paper: preparation methods of drug-loaded nanoparticles and the mechanism of crossing blood-brain barrier of nanoparticles.
Crossing the blood-brain barrier with nanoparticles

Yiqun Zhou,Zhili Peng,Elif S. Seven,Roger M. Leblanc

DOI: https://doi.org/10.1016/j.jconrel.2017.12.015

IF: 11.467

2018-01-01

Journal of Controlled Release

Abstract:The blood-brain barrier (BBB) is one of the most essential protection mechanisms in the central nervous system (CNS). It selectively allows individual molecules such as small lipid-soluble molecules to pass through the capillary endothelial membrane while limiting the passage of pathogens or toxins. However, this protection mechanism is also a major obstacle during disease state since it dramatically hinders the drug delivery. In recent years, various tactics have been applied to assist drugs to cross the BBB including osmotic disruption of the BBB and chemical modification of prodrugs. Additionally, nanoparticles (NPs)-mediated drug delivery is emerging as an effective and non-invasive system to treat cerebral diseases. In this review, we will summarize and analyze the advances in the drug delivery across the BBB using various NPs in the last decade. The NPs will cover both traditional and novel nanocarriers. The traditional nanocarriers consist of poly(butylcyanoacrylate), poly(lactic-co-glycolic acid), poly(lactic acid) NPs, liposomes and inorganic systems. In the meanwhile, novel nanocarriers such as carbon quantum dots with their recent applications in drug delivery will also be introduced. In terms of significance, this review clearly depicts the BBB structure and comprehensively describes various NPs-mediated drug delivery systems according to different NPs species. Also, the BBB penetration mechanisms are concluded in general, emphasized and investigated in each drug delivery system.

pharmacology & pharmacy,chemistry, multidisciplinary
New Insight into Brain Disease Therapy: Nanomedicines-Crossing Blood–brain Barrier and Extracellular Space for Drug Delivery

Ziqi Gu,Haishu Chen,Han Zhao,Wanting Yang,Yilan Song,Xiang Li,Yang Wang,Dan Du,Haikang Liao,Wenhao Pan,Xi Li,Yajuan Gao,Hongbin Han,Zhiqian Tong

DOI: https://doi.org/10.1080/17425247.2022.2139369

2022-01-01

Expert Opinion on Drug Delivery

Abstract:ABSTRACT Introduction Brain diseases including brain tumor, Alzheimer’s disease, Parkinson’s disease, etc. are difficult to treat. The blood–brain barrier (BBB) is a major obstacle for drug delivery into the brain. Although nano-package and receptor-mediated delivery of nanomedicine markedly increases BBB penetration, it yet did not extensively improve clinical cure rate. Recently, brain extracellular space (ECS) and interstitial fluid (ISF) drainage in ECS have been found to determine whether a drug dissolved in ISF can reach its target cells. Notably, an increase in tortuosity of ECS associated with slower ISF drainage induced by the accumulated harmful substances, such as: amyloid-beta (Aβ), α-synuclein, and metabolic wastes, causes drug delivery failure. Areas covered The methods of nano-package and receptor-mediated drug delivery and the penetration efficacy of nanomedicines across BBB and ECS are assessed. Expert opinion Invasive delivering drug via ECS and noninvasive near-infrared photo-sensitive nanomedicines may provide a promising benefit to patients with brain disease.
Investigation of the "Nose-to-Brain" Pathways in Intranasal HupA Nanoemulsions and Evaluation of Their in vivo Pharmacokinetics and Brain-Targeting Ability

Yueyao Jiang,Yichuan Jiang,Zhiying Ding,Qian Yu

DOI: https://doi.org/10.2147/IJN.S369978

2022-08-04

Abstract:Purpose: While developing huperzine A (HupA) to explore new approaches to treating Alzheimer's disease (AD), intranasal administration was proposed as an alternative route to deliver drugs into the brain. This study aimed to prepare nanoemulsions (NEs) of HupA to investigate their potential "nose-to-brain" pathways and to evaluate their pharmacokinetic and brain-targeting parameters. Methods: HupA-NE and Lf-HupA-NE that underwent surface modification with lactoferrin (Lf) were characterized to determine various physicochemical properties, such as their size, PDI, zeta potential, pH, and loading efficiency; in addition, transmission electron microscopy and stability assessments were performed. We utilized an aggregation-caused quenching (ACQ) probe to monitor intact NEs in the brains of olfactory nerve transection model and normal rats. Immunohistochemistry, pharmacokinetic and targeting index analyses were performed to investigate the in vivo effects of HupA-NE and Lf-HupA-NE. Results: Based on the live imaging results, HupA-NE and Lf-HupA-NE could be transported into the brain via nerve and blood circulation pathways. Immunohistochemical staining tests demonstrated that the efflux proteins P-gp, MRP1, and BCRP were expressed in brain tissue. NEs can inhibit efflux pumps to improve drug concentrations in the brain. The findings of this study showed that NEs (especially Lf-HupA-NE) had better pharmacokinetic profiles and a better nose-to-brain drug transport efficiency than free HupA. Conclusion: The newly designed formulations might contribute to the transport and accumulation of HupA to achieve therapeutic results. The delivery system may be a promising strategy for the brain-targeted delivery of HupA.
Natural Brain Penetration Enhancer-Modified Albumin Nanoparticles for Glioma Targeting Delivery

Jianming Liang,Caifang Gao,Ying Zhu,Chengli Ling,Qi Wang,Yongzhuo Huang,Jing Qin,Jue Wang,Weigen Lu,Jianxin Wang

DOI: https://doi.org/10.1021/acsami.8b11782

IF: 9.5

2018-01-01

ACS Applied Materials & Interfaces

Abstract:The unsatisfactory therapeutic outcome for glioma is mainly due to the poor blood-brain barrier (BBB) permeability and inefficient accumulation in the glioma area of chemotherapeutic agents. The existing drug delivery strategies can increase drug transport to the brain but are restricted by side effects and/or poor delivery efficiency. In this study, potent brain penetration enhancers were screened from the active components of aromatic resuscitation drugs used in traditional Chinese medicine. A novel glioma-targeting system based on enhancer-modified albumin nanoparticles was developed to safely and efficiently deliver drugs to the glioma regions in the brain. The nanoparticles improved the transport of nanoparticles across brain capillary endothelial cell (BCEC) monolayer by increasing endocytosis in endothelial cells and causing BBB disruption. In vivo imaging studies demonstrated that the systems could enter the brain and subsequently accumulate in glioma cells with a much higher targeting efficiency than that of transferrin-modified albumin nanoparticles. Of note, the nanoparticles could be captured and penetrate through endothelial cells fenestrae in pineal gland, which is suggestive of an effective way to deliver a nanosystem to the brain by bypassing the BBB. The nanoparticles showed good biocompatibility and negligible cytotoxicity. The results reveal an efficient and safe strategy for brain drug delivery in glioma therapy.
Low Molecular Weight Protamine-Functionalized Nanoparticles for Drug Delivery to the Brain after Intranasal Administration

Huimin Xia,Xiaoling Gao,Guangzhi Gu,Zhongyang Liu,Ni Zeng,Quanyin Hu,Qingxiang Song,Lei Yao,Zhiqing Pang,Xinguo Jiang,Jun Chen,Hongzhuan Chen

DOI: https://doi.org/10.1016/j.biomaterials.2011.09.004

IF: 14

2011-01-01

Biomaterials

Abstract:The development of new strategies for enhancing drug delivery to the brain is of great importance in diagnostics and therapeutics of central nervous diseases. Low-molecular-weight protamine (LMWP) as a cell-penetrating peptide possesses distinct advantages including high cell translocation potency, absence of toxicity of peptide itself, and the feasibility as an efficient carrier for delivering therapeutics. Therefore, it was hypothesized that brain delivery of nanoparticles conjugated with LMWP should be efficiently enhanced following intranasal administration. LMWP was functionalized to the surface of PEG-PLA nanoparticles (NP) via a maleimide-mediated covalent binding procedure. Important parameters such as particle size distribution, zeta potential and surface content were determined, which confirmed the conjugation of LMWP to the surface of nanoparticle. Using 16HBE14o- cells as the cell model, LMWP-NP was found to exhibit significantly enhanced cellular accumulation than that of unmodified NP via both lipid raft-mediated endocytosis and direct translocation processes without causing observable cytotoxic effects. Following intranasal administration of coumarin-6-loaded LMWP–NP, the AUC0–8 h of the fluorescent probe detected in the rat cerebrum, cerebellum, olfactory tract and olfactory bulb was found to be 2.03, 2.55, 2.68 and 2.82 folds, respectively, compared to that of coumarin carried by NP. Brain distribution analysis suggested LMWP-NP after intranasal administration could be delivered to the central nervous system along both the olfactory and trigeminal nerves pathways. The findings clearly indicated that the brain delivery of nanoparticles could be greatly facilitated by LMWP and the LMWP-functionalized nanoparticles appears as a effective and safe carrier for nose-to-brain drug delivery in potential diagnostic and therapeutic applications.
Getting drugs to the brain: advances and prospects of organic nanoparticle delivery systems for assisting drugs to cross the blood-brain barrier

Qiuxia Tan,Shaojing Zhao,Ting Xu,Qin Wang,Minhuan Lan,Li Yan,Xianfeng Chen

DOI: https://doi.org/10.1039/d2tb01440h

IF: 7.571

2022-10-11

Journal of Materials Chemistry B

Abstract:The blood-brain barrier (BBB) plays an irreplaceable role in protecting the central nervous system (CNS) from bloodborne pathogens. However, the BBB complicates the treatment of CNS diseases because it prevents almost all therapeutic drugs from getting into the CNS. With the growing understanding of the physiological characteristics of the BBB and the development of nanotechnology, nanomaterial-based drug delivery systems have become promising tools for delivering drugs across the BBB to the CNS. Herein, we systematically summarize the recent progress in organic-nanoparticle delivery systems for treating CNS diseases and evaluate their mechanisms in overcoming the BBB with an aim to provide a comprehensive understanding of the advantages, disadvantages, and challenges of organic nanoparticles in delivering drugs across the BBB. The review may inspire new research ideas and directions for applying nanotechnology to treat CNS diseases.

materials science, biomaterials

Up-regulating Blood Brain Barrier Permeability of Nanoparticles Via Multivalent Effect

Transferrin-conjugated, fluorescein-loaded magnetic nanoparticles for targeted delivery across the blood–brain barrier

Advancements in strategies for overcoming the blood-brain barrier to deliver brain-targeted drugs

Regulation of cerebral blood flow boosts precise brain targeting of vinpocetine-derived ionizable-lipidoid nanoparticles

Influence factors on and potential strategies to amplify receptor-mediated nanodrug delivery across the blood–brain barrier

Research Progress in Brain-Targeting Drug Delivery Systems

Strategies for transporting nanoparticles across the blood-brain barrier.

Magnetic resonance imaging with upconversion nanoprobes capable of crossing the blood-cerebrospinal fluid barrier

Advanced Noninvasive Strategies for the Brain Delivery of Therapeutic Proteins and Peptides

Brain-targeted nanoparticle drug delivery systems:research advances

Advancing Central Nervous System Drug Delivery with Microtubule-Dependent Transcytosis of Novel Aqueous Compounds

Modulation of the Blood–Brain Barrier for Drug Delivery to Brain

Overcoming the Blood-Brain Barrier for Delivering Drugs into the Brain by Using Adenosine Receptor Nanoagonist.

Clearance of Two Organic Nanoparticles from the Brain Via the Paravascular Pathway.

Study on Brain Targeted Drug Delivery Nanoparticles

Crossing the blood-brain barrier with nanoparticles

New Insight into Brain Disease Therapy: Nanomedicines-Crossing Blood–brain Barrier and Extracellular Space for Drug Delivery

Investigation of the "Nose-to-Brain" Pathways in Intranasal HupA Nanoemulsions and Evaluation of Their in vivo Pharmacokinetics and Brain-Targeting Ability

Natural Brain Penetration Enhancer-Modified Albumin Nanoparticles for Glioma Targeting Delivery

Low Molecular Weight Protamine-Functionalized Nanoparticles for Drug Delivery to the Brain after Intranasal Administration

Getting drugs to the brain: advances and prospects of organic nanoparticle delivery systems for assisting drugs to cross the blood-brain barrier